Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

@article{Blumenschein2009PhaseIM,
  title={Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.},
  author={George R. Blumenschein and Ulrich Gatzemeier and Frank V. Fossella and David J. Stewart and Lisa Cupit and Frank Cihon and James Patrick O'leary and Martin Reck},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 26},
  pages={4274-80}
}
PURPOSE Sorafenib is an oral multikinase inhibitor that targets the Ras/Raf/MEK/ERK mitogenic signaling pathway and the angiogenic receptor tyrosine kinases, vascular endothelial growth factor receptor 2 and platelet-derived growth factor receptor beta. We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy. PATIENTS AND METHODS This was… CONTINUE READING
81 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

A front-line window of opportunity phase II study of sorafenib in patients with advanced non–small-cell lung cancer: A North Central Cancer Treatment Group study

  • AA Adjei
  • J Clin Oncol 25:7547,
  • 2007
Highly Influential
4 Excerpts

A randomized discontinuation phase II study of sorafenib versus placebo in patients with non–small-cell lung cancer who have failed at least two prior chemotherapy regimens: E2501

  • J Schiller, J Lee, N Hanna
  • J Clin Oncol 26:427s, 2008
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…